Candriam SCA Portfolio holdings
Candriam is a Luxembourg asset manager with sustainable investing at its core, run as a subsidiary of New York Life Investments, with Belgian bank Belfius holding a minority stake. It was previously Dexia Asset Management and took the Candriam name in 2014, short for "Conviction AND Responsibility In Asset Management", after New York Life's asset management arm acquired it. Its funds span bonds, stocks, absolute return strategies and asset allocation, and its portfolios exclude controversial weapons, thermal coal and tobacco. In 2021 it bought a majority stake in the European real estate manager Tristan Capital Partners.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Abbott
ABT
|
+$98.2M |
| 2 |
Meta Platforms (Facebook)
META
|
+$82.9M |
| 3 |
ServiceNow
NOW
|
+$70.4M |
| 4 |
Intel
INTC
|
+$58.4M |
| 5 |
Salesforce
CRM
|
+$54.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphabet (Google) Class A
GOOGL
|
+$102M |
| 2 |
Palo Alto Networks
PANW
|
+$102M |
| 3 |
AbbVie
ABBV
|
+$68.9M |
| 4 |
Amazon
AMZN
|
+$57M |
| 5 |
NVIDIA
NVDA
|
+$54.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 41.06% |
| 2 | Healthcare | 24.01% |
| 3 | Financials | 9.02% |
| 4 | Communication Services | 7.08% |
| 5 | Consumer Discretionary | 6.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
76
Bank of New York Mellon
BNY
$103B
| $62.9M | 0.28% |
433,582
-71,045
| -14% | -$11.2M |
2016 Q1
42 quarters
|
|
77
Freeport-McMoran
FCX
$89.1B
| $62.7M | 0.28% |
892,978
+209,892
| +31% | +$14.3M |
2023 Q1
14 quarters
|
|
78
Roivant Sciences
ROIV
$30.3B
| $62.3M | 0.28% |
1,697,763
-292,747
| -15% | -$10.6M |
2025 Q1
6 quarters
|
|
79
ExxonMobil
XOM
$680B
| $60.5M | 0.27% |
370,238
+19,459
| +6% | +$3.04M |
2014 Q4
47 quarters
|
|
80
Autodesk
ADSK
$54.3B
| $60.3M | 0.27% |
287,550
-12,116
| -4% | -$2.76M |
2016 Q1
42 quarters
|
|
81
Walmart Inc
WMT
$997B
| $60.3M | 0.27% |
578,099
+58,971
| +11% | +$6.47M |
2014 Q4
47 quarters
|
|
82
Agnico Eagle Mines
AEM
$94B
| $59.7M | 0.27% |
324,156
-51,940
| -14% | -$9.21M |
2016 Q4
39 quarters
|
|
83
Hilton Worldwide Holdings Inc. Common Stock
HLT
$83.9B
| $58.9M | 0.26% |
184,432
-33,854
| -16% | -$10.9M |
2020 Q1
26 quarters
|
|
84
Morgan Stanley
MS
$298B
| $58.4M | 0.26% |
309,152
-131,176
| -30% | -$27.9M |
2014 Q4
47 quarters
|
|
85
Fortinet
FTNT
$94.1B
| $55.1M | 0.24% |
307,256
+115,648
| +60% | +$18.7M |
2019 Q1
30 quarters
|
|
86
ON Semiconductor
ON
$28.7B
| $54.8M | 0.24% |
710,393
-74,696
| -10% | -$6M |
2019 Q2
29 quarters
|
|
87
Citigroup
C
$206B
| $53.9M | 0.24% |
414,636
-39,054
| -9% | -$5.26M |
2014 Q4
47 quarters
|
|
88
Quanta Services
PWR
$91.6B
| $52.4M | 0.23% |
81,210
+442
| +0.5% | +$285K |
2022 Q4
15 quarters
|
|
89
Bank of America
BAC
$350B
| $51.8M | 0.23% |
947,750
+116,050
| +14% | +$7.07M |
2016 Q1
42 quarters
|
|
90
Deere & Co
DE
$187B
| $51.5M | 0.23% |
76,401
+15,167
| +25% | +$9.6M |
2014 Q4
47 quarters
|
|
91
BioNTech
BNTX
$21.7B
| $51.4M | 0.23% |
520,972
+23,442
| +5% | +$2.28M |
2020 Q2
25 quarters
|
|
92
GE Aerospace
GE
$356B
| $49.3M | 0.22% |
157,296
+12,091
| +8% | +$4.19M |
2014 Q4
47 quarters
|
|
93
Exelon
EXC
$47.2B
| $49.2M | 0.22% |
1,212,479
-40,288
| -3% | -$1.8M |
2014 Q4
47 quarters
|
|
94
Neurocrine Biosciences
NBIX
$17.7B
| $49.1M | 0.22% |
344,883
+83,957
| +32% | +$13.5M |
2014 Q4
47 quarters
|
|
95
Entegris
ENTG
$23.6B
| $49M | 0.22% |
317,006
-64,300
| -17% | -$9.05M |
2026 Q1
2 quarters
|
|
96
Equinix
EQIX
$106B
| $46.7M | 0.21% |
45,993
+6,236
| +16% | +$6.48M |
2015 Q4
43 quarters
|
|
97
Waste Management
WM
$95.5B
| $46.4M | 0.21% |
226,898
-75,906
| -25% | -$17M |
2014 Q4
47 quarters
|
|
98
BridgeBio Pharma
BBIO
$15.5B
| $46.4M | 0.21% |
702,845
+402,325
| +134% | +$31.3M |
2025 Q3
4 quarters
|
|
99
Adobe
ADBE
$92.5B
| $46.1M | 0.21% |
191,608
+43,537
| +29% | +$10.9M |
2014 Q4
47 quarters
|
|
100
Comfort Systems
FIX
$40.9B
| $43.6M | 0.19% |
26,274
+3,019
| +13% | +$5.07M |
2025 Q3
4 quarters
|
|
Similar funds
Candriam SCA's Q3 2026 Portfolio in Review
As of Q3 2026, Candriam SCA held 699 positions worth $22.5B, up 1.4% from $22.2B the previous quarter. Its ten largest holdings account for 34% of the portfolio.
Candriam SCA's Q3 2026 filing shows 21 new, 252 increased, 270 reduced and 51 closed positions. Its largest new stake was Zenas BioPharma: 654,833 shares worth $17.7M. The largest sale was Alphabet (Google) Class A, an estimated $102M.
By sector, the portfolio is most concentrated in Technology at 41% of assets, up from 38% a quarter earlier, followed by Healthcare and Financials.
- Candriam SCA's largest Q3 2026 buy was Zenas BioPharma: 654,833 shares worth $17.7M.
- Candriam SCA added most to Abbott in Q3 2026, an estimated $98.2M increase.
- Candriam SCA's biggest Q3 2026 reduction was Alphabet (Google) Class A, cutting an estimated $102M.
- Candriam SCA fully exited StoneX in Q3 2026, selling an estimated $46.1M.
- Candriam SCA's ten largest holdings make up 34% of its $22.5B portfolio in Q3 2026.
- Candriam SCA opened 21 new positions and closed 51 in Q3 2026.
- Candriam SCA's portfolio value rose 1.4% quarter-over-quarter to $22.5B.
Based on Candriam SCA's 13F filing for Q3 2026, filed 3 Nov 2026.